Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
-
Sono Group (SEV) Announces 10M Share Follow-on Offering
-
Sono Motors Announces Follow-on Offering
-
Sono Motors Announces Follow-on Offering
-
Form SC 13G Arbor Rapha Capital Bioh Filed by: CANTOR FITZGERALD SECURITIES
-
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX)
-
B. Riley Securities Expands Fixed Income Division with Two Key Managing Director Hires, Ji Pak and Mary Jo Collins
-
Form N-2/A CANTOR FITZGERALD SUSTAI
-
Scynexis (SCYX) Prices $45M Stock and Warrant Offering at $3/sh
-
SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
-
SeaSpine Holdings (SPNE) PT Lowered to $21 at Cantor Fitzgerald on Lower Guidance, but Analyst Reiterates "Overweight", Encourages "Investors to Acquire SPNE's Shares at Attractive Valuation"
-
Piper Sandler Expands Fixed Income Platform With Several Key Hires
-
Marinus Pharmaceuticals (MRNS) PT Raised to $28 at Cantor Fitzgerald
-
Form 424B3 Cantor Fitzgerald Income
-
Form 8-K Cantor Fitzgerald Income For: Apr 14
-
Brightwood Announces Appointment of Frederick Jelks and Chris Halajian as Directors
-
Johnson & Johnson (JNJ) Shares Dip After Revenue Miss, Suspended COVID Vaccine Sales Guidance; Results Seen as 'Mixed'
-
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
-
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
-
Orchid Island Capital Announces Estimated First Quarter 2022 Results, April 2022 Monthly Dividend and March 31, 2022 RMBS Portfolio Characteristics
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Mar 31
-
Crinetics Pharmaceuticals (CRNX) Prices 5.63M Share Offering at $22.22/sh
-
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
-
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
-
David Pett Joins RAS Realty Partners as Managing Director
-
TeraWulf (WULF) Prices $20.6 Million Public Offering of Common Stock
-
TeraWulf Inc. Announces Pricing of $20.6 Million Public Offering of Common Stock
-
Cantor Fitzgerald Reiterates Overweight Rating, $95 Price Target on I-Mab (IMAB), Expects "Greater Appreciation for the Company's Pipeline"
-
BioCardia (BCDA) Enters $10.5M Stock Sales Agreement with Cantor Fitzgerald
-
Heron Therapeutics (HRTX) and Omeros (OMER) Top Cantor Fitzgerald's Most Shorted List; Clarus (CRXT) and United Therapeutics (UTHR) Seeing Biggest Short Interest Increases
-
TeraWulf (WULF) Announces Proposed Public Offering of Common Stock
-
TeraWulf Inc. Announces Proposed Public Offering of Common Stock
-
SCHWAZZE ANNOUNCES PARTICIPATION IN UPCOMING CONFERENCES & EVENTS
-
Pfizer's (PFE) Paxlovid and Comirnaty Q1 Sales Estimates Lowered at Cantor Fitzgerald, but "Positive Investment Thesis" Maintained, Reiterates Overweight Rating
-
Aptinyx (APTX) PT Lowered to $5 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating and $335 PT on Eli Lilly (LLY), Sees CMS Decision "Better Than Anticipated" For LLY
-
UPDATE: Cantor Fitzgerald Starts StoneCo Ltd. (STNE) at Overweight
-
UPDATE: Cantor Fitzgerald Starts PagSeguro (PAGS) at Overweight
-
Form 8-K Cantor Fitzgerald Income For: Apr 04
-
Realto Hires Two Key Sales Professionals, Works to Build Upon Early Trading Success
-
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 PT, Sees Latest FMX114 Data Underscoring "Positive Investment Thesis"
-
UPDATE: Cantor Fitzgerald Assumes Bicycle Therapeutics (BCYC) at Overweight
-
Agrify to Be Featured on Industry Panel at the Cantor Fitzgerald 2nd Virtual US Cannabis Conference
-
Cantor Fitzgerald Reiterates Overweight Rating, $75 Price Target on Pfizer (PFE), Sees Strong Pipeline and M&A Potential Driving PFE Higher
-
UPDATE: Cantor Fitzgerald Assumes SI-BONE Inc. (SIBN) at Overweight, "Encourage Investors to Acquire Shares at Current Attractive Valuation" (CORRECTION)
-
Tilray (TLRY) PT Raised to $8.40 at Cantor Fitzgerald
-
Westrock Coffee Company to go Public Via Merger with Riverview Acquisition (RVAC)
-
The Stephens Group Portfolio Investment Westrock Coffee Company, a Leading Integrated Coffee, Tea, Flavors, Extracts, and Ingredients Solutions Provider, to Become a Public Company Through Business Co
-
Cantor Fitzgerald Reiterates Fortress Biotech (FBIO) at Overweight, $6 PT, "Upward Earnings Estimate Revisions and Multiple Expansion will Drive FBIO's Stock Higher"
-
Merck's "Growth Growth Prospects in 2028+ are Underappreciate - Cantor Fitzgerald Reiterates Merck (MRK) at Overweight with $107 Price Target

